Ineffectiveness of continuous quinidine gluconate infusion in the treatment of severe chloroquine-resistant Plasmodium falciparum malaria.

The drug of choice in the treatment of chloroquine-resistant Plasmodium falciparum malaria is parenteral quinine dihydrochloride. Due to limited use, the drug is not commercially available in the U.S. and must be obtained through the Centers for Disease Control (CDC) in Atlanta, Georgia. As an alternative, the CDC has developed a protocol to treat P. falciparum malaria with parenteral quinidine gluconate. Following this protocol, a 10 mg/kg loading dose of quinidine gluconate followed by a 0.02 mg/kg/min continuous infusion was administered to a 53-year-old man with severe life-threatening chloroquine-resistant P. falciparum malaria. Although the patient described did not survive, the use of parenteral quinidine gluconate still appears to be a viable alternative to parenteral quinine dihydrochloride in the treatment of severe chloroquine-resistant P. falciparum malaria.
AuthorsG K Matsuura, L A Chan
JournalDrug intelligence & clinical pharmacy (Drug Intell Clin Pharm) Vol. 22 Issue 11 Pg. 883-5 (Nov 1988) ISSN: 0012-6578 [Print] United States
PMID3069426 (Publication Type: Case Reports, Journal Article)
Chemical References
  • Chloroquine
  • Quinidine
  • Animals
  • Chloroquine (therapeutic use)
  • Drug Resistance
  • Humans
  • Infusions, Intravenous
  • Malaria (drug therapy)
  • Male
  • Middle Aged
  • Plasmodium falciparum
  • Quinidine (administration & dosage, therapeutic use)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!

Choose Username:
Verify Password:
Enter Code Shown: